You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDenosumab
Accession NumberDB06643
TypeBiotech
GroupsApproved
DescriptionDenosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption markers in patients with a variety of metastatic tumors and is being investigated in multiple clinical trials for the prevention and treatment of bone metastases. Chemically, it consists of 2 heavy and 2 light chains. Each light chain consists of 215 amino acids. Each heavy chain consists of 448 amino acids with 4 intramolecular disulfides. FDA approved on June 1, 2010.
Protein structureDb06643
Related Articles
Protein chemical formulaC6404H9912N1724O2004S50
Protein average weight144700.0 Da
Sequences
> Denosumab αOPGL-1 heavy chain sequence
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSGITGSGGSTYY
ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDPGTTVIMSWFDPWGQGTLVTV
SSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQ
SSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELL
GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ
YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
DELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKS
RWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
> Denosumab αOPGL-1 light chain sequence
EIVLTQSPGTLSLSPGERATLSCRASQSVRGRYLAWYQQKPGQAPRLLIYGASSRATGIP
DRFSGSGSGTDFTLTISRLEPEDFAVFYCQQYGSSPRTFGQGTKVEIKRTVAAPSVFIFP
PSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTL
TLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
Download FASTA Format
SynonymsNot Available
External Identifiers
  • AMG-162
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ProliaSolution60 mgSubcutaneousAmgen Canada Inc2010-08-12Not applicableCanada
ProliaSolution60 mgSubcutaneousAmgen Canada IncNot applicableNot applicableCanada
ProliaInjection60 mg/mLSubcutaneousAmgen Inc2010-06-05Not applicableUs
XgevaSolution120 mgSubcutaneousAmgen Canada Inc2011-06-06Not applicableCanada
XgevaInjection120 mg/1.7mLSubcutaneousAmgen Inc2010-11-18Not applicableUs
XgevaInjection, solution120 mgSubcutaneousAmgen Europe B.V.2011-07-13Not applicableEu
XgevaInjection, solution120 mgSubcutaneousAmgen Europe B.V.2011-07-13Not applicableEu
XgevaInjection, solution120 mgSubcutaneousAmgen Europe B.V.2011-07-13Not applicableEu
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
RanmarkDaiichi Sankyo
Brand mixturesNot Available
SaltsNot Available
Categories
UNII4EQZ6YO2HI
CAS number615258-40-7
Pharmacology
IndicationProlia is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture. It reduces the incidence of vertebral, nonvertebral, and hip fractures. Prolia is also indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer. It can also be used in men with osteoporosis at high risk for fracture or in men receiving androgen deprivation therapy for nonmetastatic prostate cancer to increase bone mass. Xgeva is indicated for the prevention of skeletal-related events in patients with bone metastases from solid tumors.
Structured Indications
PharmacodynamicsIn clinical studies, treatment with 60 mg of Prolia resulted in reduction in the bone resorption marker serum type 1 C-telopeptide (CTX) by approximately 85% by 3 days. Consistent with the physiological coupling of bone formation and resorption in skeletal remodeling, subsequent reductions in bone formation markers (i.e. osteocalcin and procollagen type 1 N-terminal peptide [PlNP]) were observed starting 1 month after the first dose of Prolia.
Mechanism of actionDenosumab is designed to target RANKL (RANK ligand), a protein that acts as the primary signal to promote bone removal/resorption. In many bone loss conditions, RANKL overwhelms the body's natural defense against bone destruction. Denosumab prevents RANKL from activating its receptor, RANK, on the surface of osteoclasts and their precursors. Prevention of the RANKL/RANK interaction inhibits osteoclast formation, function, and survival, thereby decreasing bone resorption and increasing bone mass and strength in both cortical and trabecular bone.
TargetKindPharmacological actionActionsOrganismUniProt ID
Tumor necrosis factor ligand superfamily member 11Proteinyes
antibody
HumanO14788 details
Related Articles
AbsorptionWhen 60 mg of denosumab was subcutaneously administered to healthy subjects after fasting for 12 hours, the pharmacokinetic parameters are as follows: Cmax = 6.75 mcg/mL; Tmax= 10 days (range of 3 to 21 days); AUC (0-16 weeks) = 316 mcg•day/mL. Denosumab does not accumulate following multiple doses once every 6 months. The pharmacokinetics of denosumab were not affected by the formation of antibodies.
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half life25.4 days
ClearanceNot Available
ToxicityIn patients with postmenopausal osteoporosis, the most common adverse reactions (> 5% and more common than placebo) were: back pain, pain in extremity, hypercholesterolemia, musculoskeletal pain, and cystitis. Pancreatitis has been reported in clinical trials. In male patients with osteoporosis, the most common adverse reactions (> 5% and more common than placebo) were: back pain, arthralgia, and nasopharyngitis. In patients experiencing bone loss due to hormone ablation for cancer, the most common adverse reactions (≥ 10% and more common than placebo) were: arthralgia and back pain. Pain in extremity and musculoskeletal pain have also been reported in clinical trials
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
2-MethoxyethanolThe risk or severity of adverse effects can be increased when Denosumab is combined with 2-Methoxyethanol.Experimental
9-(2-phosphonylmethoxyethyl)-2,6-diaminopurineThe risk or severity of adverse effects can be increased when Denosumab is combined with 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine.Investigational
AbataceptThe risk or severity of adverse effects can be increased when Denosumab is combined with Abatacept.Approved
abetimusThe risk or severity of adverse effects can be increased when Denosumab is combined with abetimus.Investigational
ABR-215757The risk or severity of adverse effects can be increased when Denosumab is combined with ABR-215757.Investigational
ActeosideThe risk or severity of adverse effects can be increased when Denosumab is combined with Acteoside.Investigational
AdalimumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Adalimumab.Approved
Adefovir DipivoxilThe risk or severity of adverse effects can be increased when Denosumab is combined with Adefovir Dipivoxil.Approved, Investigational
AfelimomabThe risk or severity of adverse effects can be increased when Denosumab is combined with Afelimomab.Investigational
AlefaceptThe risk or severity of adverse effects can be increased when Denosumab is combined with Alefacept.Approved, Withdrawn
AlemtuzumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Alemtuzumab.Approved, Investigational
alicaforsenThe risk or severity of adverse effects can be increased when Denosumab is combined with alicaforsen.Investigational
ALT-110The therapeutic efficacy of ALT-110 can be decreased when used in combination with Denosumab.Investigational
AltretamineThe risk or severity of adverse effects can be increased when Denosumab is combined with Altretamine.Approved
Amg 827The risk or severity of adverse effects can be increased when Denosumab is combined with Amg 827.Investigational
AmsacrineThe risk or severity of adverse effects can be increased when Denosumab is combined with Amsacrine.Approved
AnakinraThe risk or severity of adverse effects can be increased when Denosumab is combined with Anakinra.Approved
Anti-thymocyte Globulin (Rabbit)The risk or severity of adverse effects can be increased when Denosumab is combined with Anti-thymocyte Globulin (Rabbit).Approved
ApremilastThe risk or severity of adverse effects can be increased when Denosumab is combined with Apremilast.Approved, Investigational
AzacitidineThe risk or severity of adverse effects can be increased when Denosumab is combined with Azacitidine.Approved, Investigational
AzathioprineThe risk or severity of adverse effects can be increased when Denosumab is combined with Azathioprine.Approved
BasiliximabThe risk or severity of adverse effects can be increased when Denosumab is combined with Basiliximab.Approved, Investigational
BelataceptThe risk or severity of adverse effects can be increased when Denosumab is combined with Belatacept.Approved
BelimumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Belimumab.Approved
BenznidazoleThe risk or severity of adverse effects can be increased when Denosumab is combined with Benznidazole.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Denosumab is combined with Betamethasone.Approved, Vet Approved
BleomycinThe risk or severity of adverse effects can be increased when Denosumab is combined with Bleomycin.Approved
BlinatumomabThe risk or severity of adverse effects can be increased when Denosumab is combined with Blinatumomab.Approved
Brentuximab vedotinThe risk or severity of adverse effects can be increased when Denosumab is combined with Brentuximab vedotin.Approved
BriakinumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Briakinumab.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Denosumab is combined with Budesonide.Approved
BusulfanThe risk or severity of adverse effects can be increased when Denosumab is combined with Busulfan.Approved, Investigational
C1 Esterase Inhibitor (Human)The risk or severity of adverse effects can be increased when Denosumab is combined with C1 Esterase Inhibitor (Human).Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Denosumab is combined with Cabazitaxel.Approved
CanakinumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Canakinumab.Approved, Investigational
CapecitabineThe risk or severity of adverse effects can be increased when Denosumab is combined with Capecitabine.Approved, Investigational
CarboplatinThe risk or severity of adverse effects can be increased when Denosumab is combined with Carboplatin.Approved
CarmustineThe risk or severity of adverse effects can be increased when Denosumab is combined with Carmustine.Approved
CastanospermineThe risk or severity of adverse effects can be increased when Denosumab is combined with Castanospermine.Experimental
CDX-110The therapeutic efficacy of CDX-110 can be decreased when used in combination with Denosumab.Investigational
Certolizumab pegolThe risk or severity of adverse effects can be increased when Denosumab is combined with Certolizumab pegol.Approved
ChlorambucilThe risk or severity of adverse effects can be increased when Denosumab is combined with Chlorambucil.Approved
CisplatinThe risk or severity of adverse effects can be increased when Denosumab is combined with Cisplatin.Approved
CladribineThe risk or severity of adverse effects can be increased when Denosumab is combined with Cladribine.Approved, Investigational
ClofarabineThe risk or severity of adverse effects can be increased when Denosumab is combined with Clofarabine.Approved, Investigational
CorticotropinThe risk or severity of adverse effects can be increased when Denosumab is combined with Corticotropin.Approved, Vet Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Denosumab is combined with Cortisone acetate.Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when Denosumab is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe risk or severity of adverse effects can be increased when Denosumab is combined with Cyclosporine.Approved, Investigational, Vet Approved
CytarabineThe risk or severity of adverse effects can be increased when Denosumab is combined with Cytarabine.Approved, Investigational
DacarbazineThe risk or severity of adverse effects can be increased when Denosumab is combined with Dacarbazine.Approved, Investigational
DaclizumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Daclizumab.Approved, Investigational
DactinomycinThe risk or severity of adverse effects can be increased when Denosumab is combined with Dactinomycin.Approved
DasatinibThe risk or severity of adverse effects can be increased when Denosumab is combined with Dasatinib.Approved, Investigational
DaunorubicinThe risk or severity of adverse effects can be increased when Denosumab is combined with Daunorubicin.Approved
DeoxyspergualinThe risk or severity of adverse effects can be increased when Denosumab is combined with Deoxyspergualin.Investigational
DexamethasoneThe risk or severity of adverse effects can be increased when Denosumab is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dimethyl fumarateThe risk or severity of adverse effects can be increased when Denosumab is combined with Dimethyl fumarate.Approved, Investigational
DinutuximabThe risk or severity of adverse effects can be increased when Denosumab is combined with Dinutuximab.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Denosumab is combined with Docetaxel.Approved, Investigational
DoxifluridineThe risk or severity of adverse effects can be increased when Denosumab is combined with Doxifluridine.Investigational
DoxorubicinThe risk or severity of adverse effects can be increased when Denosumab is combined with Doxorubicin.Approved, Investigational
EculizumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Eculizumab.Approved, Investigational
EfalizumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Efalizumab.Approved, Investigational
EpirubicinThe risk or severity of adverse effects can be increased when Denosumab is combined with Epirubicin.Approved
EstramustineThe risk or severity of adverse effects can be increased when Denosumab is combined with Estramustine.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Denosumab is combined with Etanercept.Approved, Investigational
EtoposideThe risk or severity of adverse effects can be increased when Denosumab is combined with Etoposide.Approved
EverolimusThe risk or severity of adverse effects can be increased when Denosumab is combined with Everolimus.Approved
FingolimodThe risk or severity of adverse effects can be increased when Denosumab is combined with Fingolimod.Approved, Investigational
FloxuridineThe risk or severity of adverse effects can be increased when Denosumab is combined with Floxuridine.Approved
FludarabineThe risk or severity of adverse effects can be increased when Denosumab is combined with Fludarabine.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Denosumab is combined with Fludrocortisone.Approved
FluorouracilThe risk or severity of adverse effects can be increased when Denosumab is combined with Fluorouracil.Approved
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Denosumab.Investigational
Gallium nitrateThe risk or severity of adverse effects can be increased when Denosumab is combined with Gallium nitrate.Approved, Investigational
GemcitabineThe risk or severity of adverse effects can be increased when Denosumab is combined with Gemcitabine.Approved
Gemtuzumab ozogamicinThe risk or severity of adverse effects can be increased when Denosumab is combined with Gemtuzumab ozogamicin.Approved, Investigational, Withdrawn
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Denosumab.Investigational
Glatiramer AcetateThe risk or severity of adverse effects can be increased when Denosumab is combined with Glatiramer Acetate.Approved, Investigational
GlimepirideThe risk or severity of adverse effects can be increased when Denosumab is combined with Glimepiride.Approved
GolimumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Golimumab.Approved
GusperimusThe risk or severity of adverse effects can be increased when Denosumab is combined with Gusperimus.Investigational
HydrocortisoneThe risk or severity of adverse effects can be increased when Denosumab is combined with Hydrocortisone.Approved, Vet Approved
HydroxyureaThe risk or severity of adverse effects can be increased when Denosumab is combined with Hydroxyurea.Approved
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Denosumab is combined with Ibritumomab tiuxetan.Approved
IbrutinibThe risk or severity of adverse effects can be increased when Denosumab is combined with Ibrutinib.Approved
IcatibantThe risk or severity of adverse effects can be increased when Denosumab is combined with Icatibant.Approved
IdarubicinThe risk or severity of adverse effects can be increased when Denosumab is combined with Idarubicin.Approved
IdelalisibThe risk or severity of adverse effects can be increased when Denosumab is combined with Idelalisib.Approved
IfosfamideThe risk or severity of adverse effects can be increased when Denosumab is combined with Ifosfamide.Approved
ImatinibThe risk or severity of adverse effects can be increased when Denosumab is combined with Imatinib.Approved
ImiquimodThe risk or severity of adverse effects can be increased when Denosumab is combined with Imiquimod.Approved, Investigational
InfliximabThe risk or severity of adverse effects can be increased when Denosumab is combined with Infliximab.Approved
INGN 201The therapeutic efficacy of INGN 201 can be decreased when used in combination with Denosumab.Investigational
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Denosumab.Investigational
IrinotecanThe risk or severity of adverse effects can be increased when Denosumab is combined with Irinotecan.Approved, Investigational
L-PhenylalanineThe risk or severity of adverse effects can be increased when Denosumab is combined with L-Phenylalanine.Approved, Nutraceutical
LeflunomideThe risk or severity of adverse effects can be increased when Denosumab is combined with Leflunomide.Approved, Investigational
LenalidomideThe risk or severity of adverse effects can be increased when Denosumab is combined with Lenalidomide.Approved
LisofyllineThe risk or severity of adverse effects can be increased when Denosumab is combined with Lisofylline.Investigational
LomustineThe risk or severity of adverse effects can be increased when Denosumab is combined with Lomustine.Approved
Lx211The risk or severity of adverse effects can be increased when Denosumab is combined with Lx211.Investigational
MechlorethamineThe risk or severity of adverse effects can be increased when Denosumab is combined with Mechlorethamine.Approved
MelphalanThe risk or severity of adverse effects can be increased when Denosumab is combined with Melphalan.Approved
MepolizumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Mepolizumab.Approved, Investigational
MercaptopurineThe risk or severity of adverse effects can be increased when Denosumab is combined with Mercaptopurine.Approved
MethotrexateThe risk or severity of adverse effects can be increased when Denosumab is combined with Methotrexate.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Denosumab is combined with Methylprednisolone.Approved, Vet Approved
MitomycinThe risk or severity of adverse effects can be increased when Denosumab is combined with Mitomycin.Approved
MitoxantroneThe risk or severity of adverse effects can be increased when Denosumab is combined with Mitoxantrone.Approved, Investigational
MizoribineThe risk or severity of adverse effects can be increased when Denosumab is combined with Mizoribine.Investigational
MuromonabThe risk or severity of adverse effects can be increased when Denosumab is combined with Muromonab.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Denosumab is combined with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Denosumab is combined with Mycophenolic acid.Approved
NafamostatThe risk or severity of adverse effects can be increased when Denosumab is combined with Nafamostat.Investigational
NatalizumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Natalizumab.Approved, Investigational
NelarabineThe risk or severity of adverse effects can be increased when Denosumab is combined with Nelarabine.Approved, Investigational
NilotinibThe risk or severity of adverse effects can be increased when Denosumab is combined with Nilotinib.Approved, Investigational
ObinutuzumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Obinutuzumab.Approved
OxaliplatinThe risk or severity of adverse effects can be increased when Denosumab is combined with Oxaliplatin.Approved, Investigational
PaclitaxelThe risk or severity of adverse effects can be increased when Denosumab is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe risk or severity of adverse effects can be increased when Denosumab is combined with Palbociclib.Approved
PanobinostatThe risk or severity of adverse effects can be increased when Denosumab is combined with Panobinostat.Approved, Investigational
PazopanibThe risk or severity of adverse effects can be increased when Denosumab is combined with Pazopanib.Approved
PegaspargaseThe risk or severity of adverse effects can be increased when Denosumab is combined with Pegaspargase.Approved, Investigational
PemetrexedThe risk or severity of adverse effects can be increased when Denosumab is combined with Pemetrexed.Approved, Investigational
PentostatinThe risk or severity of adverse effects can be increased when Denosumab is combined with Pentostatin.Approved, Investigational
PimecrolimusThe risk or severity of adverse effects can be increased when Denosumab is combined with Pimecrolimus.Approved, Investigational
PirarubicinThe risk or severity of adverse effects can be increased when Denosumab is combined with Pirarubicin.Investigational
PirfenidoneThe risk or severity of adverse effects can be increased when Denosumab is combined with Pirfenidone.Investigational
PomalidomideThe risk or severity of adverse effects can be increased when Denosumab is combined with Pomalidomide.Approved
PralatrexateThe risk or severity of adverse effects can be increased when Denosumab is combined with Pralatrexate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Denosumab is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Denosumab is combined with Prednisone.Approved, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Denosumab is combined with Procarbazine.Approved
Rabies vaccineThe therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Denosumab.Approved
RilonaceptThe risk or severity of adverse effects can be increased when Denosumab is combined with Rilonacept.Approved
RituximabThe risk or severity of adverse effects can be increased when Denosumab is combined with Rituximab.Approved
RuxolitinibThe risk or severity of adverse effects can be increased when Denosumab is combined with Ruxolitinib.Approved
SecukinumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Secukinumab.Approved
SeocalcitolThe risk or severity of adverse effects can be increased when Denosumab is combined with Seocalcitol.Experimental
SiltuximabThe risk or severity of adverse effects can be increased when Denosumab is combined with Siltuximab.Approved
SirolimusThe risk or severity of adverse effects can be increased when Denosumab is combined with Sirolimus.Approved, Investigational
SorafenibThe risk or severity of adverse effects can be increased when Denosumab is combined with Sorafenib.Approved, Investigational
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Denosumab.Investigational
SteproninThe risk or severity of adverse effects can be increased when Denosumab is combined with Stepronin.Approved
StreptozocinThe risk or severity of adverse effects can be increased when Denosumab is combined with Streptozocin.Approved
SunitinibThe risk or severity of adverse effects can be increased when Denosumab is combined with Sunitinib.Approved, Investigational
TacrolimusThe risk or severity of adverse effects can be increased when Denosumab is combined with Tacrolimus.Approved, Investigational
TemozolomideThe risk or severity of adverse effects can be increased when Denosumab is combined with Temozolomide.Approved, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Denosumab is combined with Temsirolimus.Approved
TeniposideThe risk or severity of adverse effects can be increased when Denosumab is combined with Teniposide.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Denosumab is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Denosumab is combined with Teriflunomide.Approved
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Denosumab.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Denosumab is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiotepaThe risk or severity of adverse effects can be increased when Denosumab is combined with Thiotepa.Approved
TioguanineThe risk or severity of adverse effects can be increased when Denosumab is combined with Tioguanine.Approved
TocilizumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Tocilizumab.Approved
TofacitinibThe risk or severity of adverse effects can be increased when Denosumab is combined with Tofacitinib.Approved, Investigational
TopotecanThe risk or severity of adverse effects can be increased when Denosumab is combined with Topotecan.Approved, Investigational
TositumomabThe risk or severity of adverse effects can be increased when Denosumab is combined with Tositumomab.Approved
TrabectedinThe risk or severity of adverse effects can be increased when Denosumab is combined with Trabectedin.Approved, Investigational
Trastuzumab emtansineThe risk or severity of adverse effects can be increased when Denosumab is combined with Trastuzumab emtansine.Approved
TretinoinThe risk or severity of adverse effects can be increased when Denosumab is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamcinoloneThe risk or severity of adverse effects can be increased when Denosumab is combined with Triamcinolone.Approved, Vet Approved
TrofosfamideThe risk or severity of adverse effects can be increased when Denosumab is combined with Trofosfamide.Investigational
UstekinumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Ustekinumab.Approved, Investigational
VedolizumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Vedolizumab.Approved
VilanterolThe risk or severity of adverse effects can be increased when Denosumab is combined with Vilanterol.Approved
VinblastineThe risk or severity of adverse effects can be increased when Denosumab is combined with Vinblastine.Approved
VincristineThe risk or severity of adverse effects can be increased when Denosumab is combined with Vincristine.Approved, Investigational
VindesineThe risk or severity of adverse effects can be increased when Denosumab is combined with Vindesine.Approved
VinorelbineThe risk or severity of adverse effects can be increased when Denosumab is combined with Vinorelbine.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Malan J, Ettinger K, Naumann E, Beirne OR: The relationship of denosumab pharmacology and osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 Dec;114(6):671-6. doi: 10.1016/j.oooo.2012.08.439. [PubMed:23159111 ]
  2. Link [Link]
  3. Link [Link]
External Links
ATC CodesM05BX04
AHFS Codes
  • 92:24
PDB EntriesNot Available
FDA labelDownload (226 KB)
MSDSDownload (97.5 KB)
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
InjectionSubcutaneous60 mg/mL
SolutionSubcutaneous60 mg
InjectionSubcutaneous120 mg/1.7mL
Injection, solutionSubcutaneous120 mg
SolutionSubcutaneous120 mg
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2257247 No2012-09-112018-04-15Canada
CA2274987 No2012-01-242017-12-22Canada
CA2285746 No2010-09-282018-04-15Canada
CA2328140 No2012-03-132019-05-13Canada
CA2400929 No2011-05-312021-02-23Canada
Properties
StateSolid
Experimental PropertiesNot Available
Taxonomy
DescriptionNot Available
KingdomOrganic Compounds
Super ClassOrganic Acids
ClassCarboxylic Acids and Derivatives
Sub ClassAmino Acids, Peptides, and Analogues
Direct ParentPeptides
Alternative ParentsNot Available
SubstituentsNot Available
Molecular FrameworkNot Available
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antibody
General Function:
Tumor necrosis factor receptor superfamily binding
Specific Function:
Cytokine that binds to TNFRSF11B/OPG and to TNFRSF11A/RANK. Osteoclast differentiation and activation factor. Augments the ability of dendritic cells to stimulate naive T-cell proliferation. May be an important regulator of interactions between T-cells and dendritic cells and may play a role in the regulation of the T-cell-dependent immune response. May also play an important role in enhanced b...
Gene Name:
TNFSF11
Uniprot ID:
O14788
Molecular Weight:
35477.81 Da
References
  1. Lipton A, Jun S: RANKL inhibition in the treatment of bone metastases. Curr Opin Support Palliat Care. 2008 Sep;2(3):197-203. doi: 10.1097/SPC.0b013e32830baac2. [PubMed:18685421 ]
  2. Westenfeld R, Ketteler M, Brandenburg VM: Anti-RANKL therapy--implications for the bone-vascular-axis in CKD? Denosumab in post-menopausal women with low bone mineral density. Nephrol Dial Transplant. 2006 Aug;21(8):2075-7. Epub 2006 May 15. [PubMed:16702197 ]
Comments
comments powered by Disqus
Drug created on March 19, 2008 10:43 / Updated on August 17, 2016 12:24